Gram Research analysis shows that Lactobacillus plantarum, a common probiotic bacteria, reduced intestinal inflammation by 37 to 68 percent across multiple laboratory models of Crohn’s disease. In mice with active disease flare-ups, the probiotic improved weight maintenance, strengthened the gut barrier, and lowered inflammation markers significantly. Early treatment before disease developed showed the strongest benefits, suggesting probiotics might work best as a preventive approach. However, these results come from mouse studies, and human clinical trials are needed to confirm whether this probiotic would help people with Crohn’s disease.
Researchers tested a common probiotic called Lactobacillus plantarum to see if it could help control Crohn’s disease, a painful digestive condition. Using mouse models that mimic human Crohn’s disease, scientists found that this probiotic reduced intestinal inflammation, helped the gut lining heal better, and even prevented disease from starting in young mice. The bacteria appeared to work by strengthening the barrier that lines the intestines and reducing harmful inflammation. While these results are promising, the research was done in mice, so scientists will need to test whether it works the same way in people with Crohn’s disease.
Key Statistics
A 2026 research study in mice found that Lactobacillus plantarum reduced inflammation scores by 42 percent in acute Crohn’s-like disease and by 37 percent in chronic disease compared to untreated controls.
According to research reviewed by Gram, early-life probiotic intervention reduced intestinal permeability by 68 percent in mice before disease naturally developed, suggesting prevention may be more effective than treatment after disease starts.
The 2026 study showed that Lactobacillus plantarum extended disease remission in mice with chronic Crohn’s-like disease, with tissue inflammation scores dropping from 9.6 to 6.0 on a severity scale.
The Quick Take
- What they studied: Whether a probiotic bacteria called Lactobacillus plantarum could reduce intestinal inflammation and help control Crohn’s disease symptoms in laboratory mice.
- Who participated: Three different groups of laboratory mice bred to naturally develop Crohn’s-like disease. The mice were tested at different life stages: young mice before disease started, older mice with active disease, and mice given chemicals to trigger flare-ups.
- Key finding: Lactobacillus plantarum reduced intestinal inflammation scores by about 42 percent in mice with active disease flare-ups and by about 37 percent in mice with chronic disease, compared to mice that didn’t receive the probiotic.
- What it means for you: This research suggests probiotics might help people with Crohn’s disease manage symptoms and reduce flare-ups, but human studies are needed to confirm these results. People with Crohn’s should talk to their doctor before trying new probiotics, as individual responses vary.
The Research Details
Scientists used three different laboratory mouse models that naturally develop Crohn’s-like disease to test whether Lactobacillus plantarum could help. In the first model, they gave mice a chemical called dextran sodium sulfate to trigger an acute flare-up similar to a Crohn’s attack. In the second model, they used older mice that already had chronic intestinal disease and gave them a medication to put the disease into remission, then watched whether the probiotic kept them in remission longer. In the third model, they gave the probiotic to young mice before disease naturally developed to see if it could prevent the disease from starting.
For each model, researchers measured multiple markers of intestinal health. They tracked body weight changes, tested stool samples for signs of inflammation, measured how leaky the intestinal barrier had become, used a tiny camera to look inside the colon, and examined tissue samples under a microscope. This multi-method approach gave them a complete picture of how the probiotic affected different aspects of the disease.
The probiotic was administered to the mice over several weeks, and measurements were taken at regular intervals to track changes over time. Control groups of mice received the same treatment but without the probiotic, allowing researchers to compare results directly.
This research approach matters because it tests the probiotic in multiple disease scenarios that mirror different aspects of human Crohn’s disease. By testing prevention, treatment during active disease, and maintenance during remission, researchers could see whether the probiotic works at different disease stages. The combination of clinical measurements, imaging, and tissue analysis provides strong evidence for how the probiotic actually works in the body, not just whether symptoms improve.
This study was published in a peer-reviewed journal focused on probiotics research, meaning other experts reviewed the work before publication. The researchers used multiple established mouse models of Crohn’s disease rather than just one, which strengthens confidence in the findings. They measured inflammation using several different methods rather than relying on a single test. However, this research was conducted entirely in mice, so results may not directly translate to humans. The study did not specify the exact number of mice used in each group, which makes it harder to evaluate statistical power. No information was provided about funding sources or potential conflicts of interest.
What the Results Show
In mice with acute disease flare-ups caused by chemical treatment, Lactobacillus plantarum significantly improved multiple measures of intestinal health. Mice receiving the probiotic maintained their body weight better than control mice, their colons remained longer and healthier, and their intestinal barrier function improved, meaning less harmful material leaked through the gut lining. Inflammation markers in stool samples dropped from 5.3 to 3.1 (a 42 percent reduction), and colonoscopy scores showed less visible inflammation in the colon.
In older mice with chronic Crohn’s-like disease that had been put into remission with medication, the probiotic extended how long the remission lasted and reduced the severity of disease relapse when it did occur. Mice receiving the probiotic maintained better weight, had less intestinal leakiness, and showed lower inflammation levels. Tissue samples showed significantly less damage, with inflammation scores dropping from 9.6 to 6.0 (a 37 percent reduction).
When given to young mice before disease naturally developed, the probiotic prevented or greatly reduced disease onset. These mice developed much less severe intestinal damage and inflammation compared to untreated mice. Intestinal permeability scores dropped from 1.9 to 0.6 (a 68 percent reduction), suggesting the probiotic strengthened the gut barrier before disease could take hold.
Across all three disease models, the probiotic appeared to work by improving the integrity of the intestinal barrier (the protective lining of the gut) and reducing the overall inflammatory response in the intestines. This suggests the bacteria may help restore balance to the immune system in the gut.
The research revealed that early intervention with the probiotic appeared most effective, with the largest reductions in disease severity seen when treatment started before disease developed. This suggests that probiotics might work better as a preventive measure than as a treatment for established disease, though the probiotic still helped in all scenarios tested. The consistent improvement across multiple measurement methods (weight, stool markers, tissue damage, and imaging) suggests the probiotic’s effects were real and not due to chance or measurement error.
This research builds on earlier studies showing that gut bacteria play a major role in Crohn’s disease development. Previous research identified that people with Crohn’s disease have different bacterial communities in their gut compared to healthy people. This study provides experimental evidence that adding back beneficial bacteria like Lactobacillus plantarum can help restore intestinal health. The findings align with other probiotic research showing that certain bacteria can strengthen the gut barrier and reduce inflammation, though most previous studies focused on other bacterial strains or different diseases.
The most important limitation is that this research was conducted entirely in laboratory mice, not in humans. Mouse models of disease don’t always behave the same way as human disease, so results may not directly apply to people with Crohn’s disease. The study did not specify how many mice were used in each group, making it difficult to assess whether the sample size was large enough to draw reliable conclusions. The research did not test different doses of the probiotic or compare it to existing Crohn’s disease medications, so it’s unclear how effective it might be compared to current treatments. Additionally, the study did not examine whether the probiotic’s benefits lasted long-term or what happened after treatment stopped. The mice were given the probiotic in controlled laboratory conditions, which may not reflect how well it would work in real-world human use where diet, stress, and other factors vary.
The Bottom Line
Based on this research, Lactobacillus plantarum shows promise as a potential complementary treatment for Crohn’s disease, but human clinical trials are needed before it can be recommended as a standard treatment. People with Crohn’s disease who are interested in trying probiotics should discuss this with their gastroenterologist first, as individual responses vary and probiotics should not replace established medications. The research suggests that early intervention might be most beneficial, but this needs confirmation in human studies. Confidence level: Moderate for laboratory evidence; Low for human application until clinical trials are completed.
People with Crohn’s disease or those at high risk for developing it should pay attention to this research, as it suggests a potential new treatment approach. Family members of people with Crohn’s disease may also be interested, as the research hints that early intervention might prevent disease development. Healthcare providers treating inflammatory bowel disease should monitor this research as it progresses toward human trials. People without Crohn’s disease or inflammatory bowel disease should not assume this probiotic will help them, as the research is specific to this disease.
In the mouse studies, improvements in inflammation markers appeared within weeks of starting the probiotic. However, the timeline for human benefit is unknown. If this research leads to human clinical trials, it typically takes 2 to 5 years to complete Phase 1 and Phase 2 trials, and several more years for Phase 3 trials. Even if human trials show promise, it could be 5 to 10 years before Lactobacillus plantarum might become an approved medical treatment for Crohn’s disease. People should not expect immediate results if they try this probiotic, and benefits may take weeks to months to appear, if they occur at all.
Frequently Asked Questions
Can probiotics help with Crohn’s disease symptoms?
Research shows Lactobacillus plantarum reduced intestinal inflammation by 37 to 68 percent in mouse models of Crohn’s disease. However, these results are from laboratory studies, not humans. Talk to your doctor before trying probiotics, as individual responses vary and they shouldn’t replace current medications.
Which probiotic is best for inflammatory bowel disease?
This study specifically tested Lactobacillus plantarum and found it reduced inflammation in mouse models. Different probiotics may work differently, and research on other strains for inflammatory bowel disease is ongoing. Your gastroenterologist can recommend probiotics based on current evidence and your individual situation.
How long does it take for probiotics to work for Crohn’s disease?
In mouse studies, improvements appeared within weeks. For humans, the timeline is unknown since human clinical trials haven’t been completed yet. If you try a probiotic, allow 8 to 12 weeks to assess whether it helps your symptoms, and track changes carefully.
Can probiotics prevent Crohn’s disease from developing?
This study found that giving Lactobacillus plantarum to young mice before disease developed reduced disease severity by 68 percent. This suggests probiotics might help prevent disease, but this has only been tested in mice. Human prevention studies are needed to know if this works in people.
Is Lactobacillus plantarum safe for people with Crohn’s disease?
Lactobacillus plantarum is generally recognized as safe, but people with Crohn’s disease should consult their doctor before starting any probiotic. Some people with severe immunosuppression or active disease may need to avoid certain probiotics. Your healthcare provider can assess whether it’s appropriate for your specific situation.
Want to Apply This Research?
- Track daily bowel movement consistency (using the Bristol Stool Scale: 1-7 rating), abdominal pain level (0-10 scale), and energy level (0-10 scale) for at least 4 weeks before and after starting a Lactobacillus plantarum supplement to establish a personal baseline and monitor for changes.
- If you have Crohn’s disease and want to explore this probiotic, start by logging your current symptoms in the app for 2 weeks to establish a baseline. Then, after consulting with your doctor, add a Lactobacillus plantarum supplement and continue logging the same symptoms weekly. Use the app’s comparison feature to see if your symptom patterns change over 8 to 12 weeks.
- Create a weekly symptom check-in routine that tracks stool consistency, pain levels, and flare-up frequency. Set monthly reminders to review trends and share data with your healthcare provider. If you notice improvements, continue tracking to identify which factors (diet, stress, sleep) correlate with better outcomes. If no improvement appears after 8 to 12 weeks, discuss with your doctor whether to continue or try a different approach.
This article summarizes laboratory research in mice and should not be considered medical advice. Lactobacillus plantarum has not been approved by the FDA as a treatment for Crohn’s disease, and human clinical trials are still needed. People with Crohn’s disease or other gastrointestinal conditions should consult their gastroenterologist or healthcare provider before starting any probiotic supplement. Probiotics should not replace established medical treatments for Crohn’s disease. Individual responses to probiotics vary, and what works for one person may not work for another. If you experience worsening symptoms after starting a probiotic, stop use and contact your healthcare provider immediately.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.